Sustainability & Climate

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

A new program in Michigan uses AI to analyze existing CT scans, detecting silent heart risks and connecting patients to care before symptoms even appear.

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

Boundless Futures Foundation and Ladies Who Launch partner to provide funding and vital resources, creating a new ecosystem for mission-driven female founders.

A new network of local recycling facilities aims to solve the e-waste gap for small businesses, boosting data security and domestic materials recovery.

Prestigious toxicology awards recognize UL Research Institutes' vital work on vaping health risks and innovative methods for assessing chemical safety.

Neurotech leader BrainsWay adjusts its share structure in a move to enhance liquidity, clarify valuation, and attract a broader base of global investors.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

A new report reveals why some indie restaurants thrive while others struggle, and it’s not just hard work. It's about access to strategic tools.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

The world's largest bedding company raises its dividend for the sixth time in five years, flexing financial muscle despite mixed signals from Wall Street.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

Two small businesses from Pennsylvania are finding massive success in Asia, leveraging Coupang's AI-powered platform to bypass traditional export hurdles.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

London-based Resurrect Bio lands $8.1M led by Corteva to scale its AI-driven gene-editing platform, aiming to resurrect natural plant immunity.

A new study uses PET-CT scans to track CIT-013, a first-in-class antibody targeting the root cause of inflammation in rheumatoid arthritis and HS.

Nawal Ouzren steps down as CEO for personal reasons just after a €60M financing. Chairman Amit Munshi takes over as the biotech faces key milestones.